Vai al contenuto
  • Fondazione Michelangelo
    • About Us
    • Our Story
    • Mission
    • Support FM
    • Contacts
  • Michelangelo Tech
    • CRO
    • Trials
    • MT Team
  • News & Update
  • IT
Menu
  • Fondazione Michelangelo
    • About Us
    • Our Story
    • Mission
    • Support FM
    • Contacts
  • Michelangelo Tech
    • CRO
    • Trials
    • MT Team
  • News & Update
  • IT
Search
Close this search box.
Search
Close this search box.

Category: News & Update

A meta-analysis on anthracycline-taxane chemotherapy in early stage breast cancer

Anthracycline plus taxane regimens are among the most efficacious at reducing breast cancer recurrence and death, with optimal doses providing the greatest benefits

Atezolizumab and carboplatin in metastatic lobular breast cancer

The GELATO trial shows the feasibility of trials specifically designed for invasive lobular breast cancer and demonstrate antitumor activity of PD-L1 blockade and carboplatin

The role of pathologic complete response in early breast cancer after neoadjuvant therapy

Patients with HER2-positive early breast cancer who achieve a pathologic complete response have far better survival outcomes than patients who do not, but other prognostic factors count too

Prognostic value of ctDNA in triple-negative breast cancer

ctDNA and residual cancer burden after neoadjuvant systemic therapy are independently prognostic in triple-negative breast cancer patients

Irradiation or no irradiation after surgery in early breast cancer

The effects of omission of radiotherapy after surgery on local or distal recurrence and survival in women with low-risk, hormone receptor–positive early breast cancer

The ALPHABET study on breast cancer is enrolling patients

Enrollment of patients with HER2+ metastatic breast cancer and PIK3CA mutation has been started at IEO, to evaluate the addition of alpelisib to current therapies

Olaparib in BRCA-mutated, HER-2 negative metastatic breast cancer

Olaparib significantly prolonged progression-free survival compared to chemotherapy, particularly in first line patients.

Federated learning to predicting chemotherapy response in triple-negative breast cancer

This multicentric machine learning model improves performance of local models in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.

Fondazione Michelangelo at the San Antonio Breast Cancer Symposium

Foundation’s experts and data in key educational sessions to share knowledge on the role of neoadjuvant therapy and imaging mass cytometry in breast cancer

Triple negative breast cancer, new therapeutic options and future strategies

Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer

← older

@Fondazione Michelangelo | All rights reserved 2023 | Privacy Policy | Cookie Policy

Privacy Policy

Connect with us

segreteria@fondazionemichelangelo.org

@Fondazione Michelangelo | All rights reserved 2023 | Privacy Policy | Cookie Policy

Privacy Policy
  • Home page
  • Fondazione Michelangelo
    • About Us
    • Mission
    • Our Story
    • Support FM
    • Contacts
  • Michelangelo Tech
    • CRO
    • Trials
    • MT Team
  • News & Update
  • IT